Phosphonated Calixarenes For The Targeted Intracellular Delivery Of Anticancer Agents
Funder
National Health and Medical Research Council
Funding Amount
$322,267.00
Summary
Many anticancer drugs have severe side effects due to their potency and non-specificity of action. To improve the treatment outcome for thousands of cancer patients, we aim to engineer calixarene-based nanocarriers that bypass normal tissues to selectively deposit drugs and imaging agents into tumour cells. Such delivery systems will optimize the performance of a host of anticancer agents that act within cells, and enable drug treatment and monitoring to be simultaneously realised.
Novel Inhalation Formulation Of Colistin And Combination Therapy Against Gram-negative 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$513,896.00
Summary
Respiratory infections caused by multidrug-resistant Gram-negative bacteria are major health problems for Australians. Colistin is the last-resort defense in most cases. However, parenteral administration of colistin will cause serious side effects. This proposal applies an interdisciplinary approach using aerosol particle engineering, functional lung imaging and antimicrobial pharmacology to develop and characterise novel inhaled powder formulations of colistin and its rational combinations.
Novel Inhalation Formulation Of Bacteriophages Against ‘superbugs’ Causing Respiratory Infections
Funder
National Health and Medical Research Council
Funding Amount
$563,621.00
Summary
Emergence of superbugs has led to life-threatening respiratory infections that are resistant to most antibiotics. There is an urgent need for alternative treatments not relying on antibiotics. Bacteriophages (or ‘bacteria eaters’) are natural predators of bacteria and are unaffected by antibiotic resistance. This multi-disciplinary project will develop novel therapeutics using inhaled bacteriophages against bacterial infections in the lungs.
Engineering Powder Aerosols Of Antibacterial Nanomedicines For Treatment Of Respiratory Infections
Funder
National Health and Medical Research Council
Funding Amount
$195,338.00
Summary
This project aims to apply cutting-edge nanotechnology to develop new inhalation therapy for respiratory infections by delivering antibiotics directly to the lungs. The expected outcomes of this work are more efficacious, safer and cost effective treatments for patients suffering from respiratory infectious diseases such as pneumonia.
CSI-Sydney: New Technologies To Treat Chronic Sinus Infection
Funder
National Health and Medical Research Council
Funding Amount
$412,213.00
Summary
Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet amazingly, has no specific cure or effective treatment. Our multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses and a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$560,659.00
Summary
New drugs for cancer therapy are essential to develop that overcome resistance to standard chemotherapeutics. We have developed potent anti-cancer chelators that bind to the abundant plasma protein, albumin. Our studies showed increased tumour cell uptake of the chelator, Dp44mT, mediated by albumin. We will elucidate the mechanisms of their albumin-mediated uptake, with the aim to implement albumin nanoparticles as carriers of novel chelators to selectively target tumours.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Novel agents that bind essential metals have emerged as a potential avenue for cancer therapy. My laboratory has developed potent anti-cancer agents, such as Dp44mT, that bind to the plasma protein, albumin. Notably, the uptake of Dp44mT into tumour cells was increased in the presence of albumin. My research will examine the mechanisms in the albumin-mediated increase in Dp44mT uptake into tumour cells, with the goal to develop albumin nanoparticles to selectively deliver our agents to tumours.
Targeting Cystic Fibrosis Using A Novel Inhalation Therapy
Funder
National Health and Medical Research Council
Funding Amount
$421,545.00
Summary
Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.
Understanding The Mechanisms Of Nanomedicine Absorption From The Lungs And The Application Of This Knowledge To Improving The Delivery Of Chemotherapeutic Nanomedicines Towards Primary And Secondary Lung Cancers
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
The administration of chemotherapeutic 'nanomedicines' via the lungs has the capacity to improve the specific delivery of toxic anti-cancer drugs specifically towards primary and metastatic lung cancers. This project aims to evaluate how nanomedicines are absorbed from the lungs after an inhaled dose, and how they can be best developed as inhaled chemotherapeutics for the treatment of lung cancers.
Drug Targeting To Sites Of Lymph-adipose Interaction To Transform The Treatment Of Disease
Funder
National Health and Medical Research Council
Funding Amount
$515,172.00
Summary
Insulin resistance (IR) underpins the development of inadequately treated heart and metabolic diseases such as type 2 diabetes. Recently we demonstrated that high fat diets promote increased leakage of fluid from lymph vessels to abdominal fat, and that increased access of lymph fluid to fat stimulates fat expansion and changes in fat function that promote IR. This project seeks to optimise novel drug delivery strategies that target lymph and fat and more effectively treat IR.